{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:03:10Z","timestamp":1780117390403,"version":"3.54.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12325-026-03580-w","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T17:03:20Z","timestamp":1775927000000},"page":"2704-2721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health-Related Quality of Life and Work-Related Outcomes in People with Obesity or Overweight Treated with Tirzepatide or Other Obesity Medications: United States Results from the Adelphi Real World Obesity Disease Specific Programme\u2122"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-9175","authenticated-orcid":false,"given":"Theresa Hunter","family":"Gibble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Leith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya Kokil","family":"Raikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"Ashok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Artime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"1","key":"3580_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12889-021-12449-2","volume":"22","author":"J Hecker","year":"2022","unstructured":"Hecker J, Freijer K, Hiligsmann M, Evers S. Burden of disease study of overweight and obesity; the societal impact in terms of cost-of-illness and health-related quality of life. BMC Public Health. 2022;22(1):46.","journal-title":"BMC Public Health"},{"key":"3580_CR2","unstructured":"Federation, W.O., World Obesity Atlas 2025. 2025: London. p. 1\u2013275."},{"key":"3580_CR3","doi-asserted-by":"publisher","first-page":"205031212413130","DOI":"10.1177\/20503121241313082","volume":"13","author":"E Artime","year":"2025","unstructured":"Artime E, et al. Experiences and overall impact reported by people living with obesity: results from a multinational study. SAGE Open Med. 2025;13:20503121241313080.","journal-title":"SAGE Open Med"},{"issue":"4","key":"3580_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/03007995.2025.2486167","volume":"41","author":"T Tanaka","year":"2025","unstructured":"Tanaka T, et al. Real-world cross-sectional study evaluating patient characteristics, disease burden, and treatment approaches in people with obesity disease in Japan. Curr Med Res Opin. 2025;41(4):617\u201326.","journal-title":"Curr Med Res Opin"},{"key":"3580_CR5","doi-asserted-by":"publisher","first-page":"100171","DOI":"10.1016\/j.obpill.2025.100171","volume":"14","author":"J Glass","year":"2025","unstructured":"Glass J, et al. Management and impact of obesity in Canada: a real-world survey of people with obesity and their physicians. Obes Pillars. 2025;14:100171.","journal-title":"Obes Pillars"},{"issue":"1","key":"3580_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1186\/s12889-021-10523-3","volume":"21","author":"SD Amenyah","year":"2021","unstructured":"Amenyah SD, Murphy J, Fenge LA. Evaluation of a health-related intervention to reduce overweight, obesity and increase employment in France and the United Kingdom: a mixed-methods realist evaluation protocol. BMC Public Health. 2021;21(1):582.","journal-title":"BMC Public Health"},{"key":"3580_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/CEOR.S504462","volume":"17","author":"MA Nagi","year":"2025","unstructured":"Nagi MA, et al. The burden of obesity in Saudi Arabia: a real-world cost-of-illness study. Clinicoecon Outcomes Res. 2025;17:233\u201346.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"3580_CR8","doi-asserted-by":"publisher","first-page":"e775","DOI":"10.1002\/osp4.775","volume":"10","author":"S Shinde","year":"2024","unstructured":"Shinde S, Tran AT, Jerry M, Lee CJ. Work loss among privately insured employees with overweight and obesity in the United States. Obes Sci Pract. 2024;10(4):e775.","journal-title":"Obes Sci Pract"},{"issue":"8","key":"3580_CR9","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/s41366-023-01325-1","volume":"47","author":"M Evans","year":"2023","unstructured":"Evans M, et al. Obesity-related complications, healthcare resource use and weight loss strategies in six European countries: the RESOURCE survey. Int J Obes (Lond). 2023;47(8):750\u20137.","journal-title":"Int J Obes (Lond)"},{"key":"3580_CR10","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.2147\/DMSO.S245486","volume":"13","author":"H Rozjabek","year":"2020","unstructured":"Rozjabek H, Fastenau J, LaPrade A, Sternbach N. Adult obesity and health-related quality of life, patient activation, work productivity, and weight loss behaviors in the United States. Diabetes Metab Syndr Obes. 2020;13:2049\u201355.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"3580_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-006351","author":"A Okunogbe","year":"2021","unstructured":"Okunogbe A, et al. Economic impacts of overweight and obesity: current and future estimates for eight countries. BMJ Glob Health. 2021. https:\/\/doi.org\/10.1136\/bmjgh-2021-006351.","journal-title":"BMJ Glob Health"},{"issue":"12","key":"3580_CR12","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41366-023-01376-4","volume":"47","author":"J Pearson-Stuttard","year":"2023","unstructured":"Pearson-Stuttard J, et al. Real-world costs of obesity-related complications over eight years: a US retrospective cohort study in 28,500 individuals. Int J Obes (Lond). 2023;47(12):1239\u201346.","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"3580_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1186\/s12889-022-12835-4","volume":"22","author":"C Hochsmann","year":"2022","unstructured":"Hochsmann C, et al. Association between weight loss, change in physical activity, and change in quality of life following a corporately sponsored, online weight loss program. BMC Public Health. 2022;22(1):451.","journal-title":"BMC Public Health"},{"issue":"15 Suppl","key":"3580_CR14","first-page":"S288","volume":"28","author":"MA Cornier","year":"2022","unstructured":"Cornier MA. A review of current guidelines for the treatment of obesity. Am J Manag Care. 2022;28(15 Suppl):S288\u201396.","journal-title":"Am J Manag Care"},{"issue":"1","key":"3580_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13098-023-01233-4","volume":"16","author":"W Coutinho","year":"2024","unstructured":"Coutinho W, Halpern B. Pharmacotherapy for obesity: moving towards efficacy improvement. Diabetol Metab Syndr. 2024;16(1):6.","journal-title":"Diabetol Metab Syndr"},{"issue":"3","key":"3580_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"10402","key":"3580_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613\u201326.","journal-title":"Lancet"},{"issue":"10","key":"3580_CR18","doi-asserted-by":"publisher","first-page":"6023","DOI":"10.1111\/dom.16600","volume":"27","author":"GK Dawwas","year":"2025","unstructured":"Dawwas GK, Samuels JM, Stein CM. Shifting obesity treatment paradigms: Trends of glucagon-like peptide-1 receptor agonists and bariatric surgery in the United States. Diabetes Obes Metab. 2025;27(10):6023.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"3580_CR19","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, et al. Real-world physician and patient behaviour across countries: disease-specific programmes\u2014a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"3580_CR20","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes. Curr Med Res Opin. 2023;39(12):1707\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"3580_CR21","doi-asserted-by":"publisher","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, et al. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8):e010352.","journal-title":"BMJ Open"},{"key":"3580_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"3580_CR23","unstructured":"Maruish, M.E., User\u2019s manual for the SF-36v2 Health Survey (3rd ed.). 3rd ed ed., Lincoln, RI: QualityMetric Incorporated."},{"issue":"3","key":"3580_CR24","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/rheumatology\/keaa453","volume":"60","author":"A Gomez","year":"2021","unstructured":"Gomez A, et al. Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(3):1260\u201372.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3580_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12955-019-1211-0","volume":"17","author":"AAS Jaber","year":"2019","unstructured":"Jaber AAS, Ibrahim B. Health-related quality of life of patients with multidrug-resistant tuberculosis in Yemen: prospective study. Health Qual Life Outcomes. 2019;17(1):142.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"3580_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"3580_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/occmed\/kqaf097","author":"K Walker-Bone","year":"2025","unstructured":"Walker-Bone K. The work productivity and activity impairment (WPAI) questionnaire. Occup Med. 2025. https:\/\/doi.org\/10.1093\/occmed\/kqaf097.","journal-title":"Occup Med"},{"issue":"17","key":"3580_CR28","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1093\/eurjpc\/zwac187","volume":"29","author":"F Lopez-Jimenez","year":"2022","unstructured":"Lopez-Jimenez F, et al. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. Eur J Prev Cardiol. 2022;29(17):2218\u201337.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"3580_CR29","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/dom.14897","volume":"25","author":"M Evans","year":"2023","unstructured":"Evans M, et al. Eight-year trends in obesity-related complications and health care cost progression in a US population with obesity: a retrospective cohort study. Diabetes Obes Metab. 2023;25(2):536\u201344.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"3580_CR30","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.1111\/dom.15836","volume":"26","author":"J Pearson-Stuttard","year":"2024","unstructured":"Pearson-Stuttard J, et al. Ten-year progression of obesity-related complications in a population with overweight and obesity in the UK: a retrospective open cohort study. Diabetes Obes Metab. 2024;26(11):5056\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"3580_CR31","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"22","key":"3580_CR32","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly AS, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"3580_CR33","doi-asserted-by":"publisher","first-page":"e2116595","DOI":"10.1001\/jamanetworkopen.2021.16595","volume":"4","author":"KM Pantalone","year":"2021","unstructured":"Pantalone KM, et al. Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity: A Randomized Clinical Trial. JAMA Netw Open. 2021;4(7):e2116595.","journal-title":"JAMA Netw Open"},{"key":"3580_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19094981","author":"R Pojednic","year":"2022","unstructured":"Pojednic R, D\u2019Arpino E, Halliday I, Bantham A. The benefits of physical activity for people with obesity, independent of weight loss: a systematic review. Int J Environ Res Public Health. 2022. https:\/\/doi.org\/10.3390\/ijerph19094981.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"3580_CR35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/dom.16046","volume":"27","author":"KA Gudzune","year":"2025","unstructured":"Gudzune KA, et al. Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: results from the SURMOUNT-1 study. Diabetes Obes Metab. 2025;27(2):539\u201350.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"3580_CR36","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1111\/dom.16290","volume":"27","author":"ER Hankosky","year":"2025","unstructured":"Hankosky ER, et al. Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: results from the Optum Market Clarity database. Diabetes Obes Metab. 2025;27(5):2810\u201321.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"3580_CR37","doi-asserted-by":"publisher","first-page":"101636","DOI":"10.1016\/j.diabet.2025.101636","volume":"51","author":"ER Hankosky","year":"2025","unstructured":"Hankosky ER, et al. Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States. Diabetes Metab. 2025;51(3):101636.","journal-title":"Diabetes Metab"},{"issue":"5","key":"3580_CR38","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/oby.24002","volume":"32","author":"X-H Pan","year":"2024","unstructured":"Pan X-H, Yip Han Chin BT, Lee ECZ, Kong G, Chong B, Kueh M, et al. Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. Obesity. 2024;32(5):840\u201356.","journal-title":"Obesity"},{"issue":"9","key":"3580_CR39","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","volume":"184","author":"PJ Rodriguez","year":"2024","unstructured":"Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Int Med. 2024;184(9):1056\u201364.","journal-title":"JAMA Int Med"},{"issue":"Suppl 3","key":"3580_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161365.GL","volume":"22","author":"WT Garvey","year":"2016","unstructured":"Garvey WT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1\u2013203.","journal-title":"Endocr Pract"},{"issue":"8","key":"3580_CR41","first-page":"656","volume":"333","author":"S Anderer","year":"2025","unstructured":"Anderer S. FDA approves Tirzepatide as first drug for obstructive sleep apnea. JAMA. 2025;333(8):656.","journal-title":"JAMA"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03580-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03580-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03580-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:51:25Z","timestamp":1780116685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03580-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3580"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03580-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Theresa Hunter Gibble, Claire Gerber, Sonya Kokil Raikar, Esther Artime, and Gayathri Ashok are employees and shareholders of Eli Lilly and Company. Andrea Leith and Lewis Harrison are employees of Adelphi Real World.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The DSP complied with the European Pharmaceutical Market Research Association code of conduct and ARW standard operating procedures. This study was conducted in accordance with ethical principles originating from the Declaration of Helsinki and is consistent with Good Pharmacoepidemiology Practices and applicable laws and regulations. Ethics exemption was obtained from the Pearl Institutional Review Board in the US (approval no: #22-ADRW-136). Using a checkbox, all PwO provided their informed consent prior to the use of their anonymized and aggregated data for research and publication in scientific journals. Data were collected so that PwO and physicians could not be identified directly; all data were aggregated and de-identified before receipt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}